Mainstay Lands $108M To Support Launch Of ReActiv8 Back Pain Device
The company has begun the US launch of the ReActiv8 implantable neurostimulator for treating low back pain in the US while expanding commercialization in Australia and Europe.
You may also be interested in...
Mainstay Medical says it will move forward with a US PMA application for its ReActiv8 neuromodulation therapy for chronic back pain even though the ReActiv8 clinical trial failed to reach its primary endpoint.
Simplify’s total disc replacement complements NuVasive’s C360 line of cervical repair surgery devices, addressing a market that could eventually be worth $2.6bn.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.